NHS pilots rapid brain tumour test delivering results in hours
NHS England begins piloting a rapid genomic brain tumour test that slashes waiting times from eight weeks to two hours, enabling faster treatment.
Stock photo for illustration only, not from the actual event
- NHS England pilots a rapid genomic brain tumour testing technology
- Tests reduce diagnosis waiting time from 8 weeks to just 2 hours
- Surgeons can receive accurate tumour types while patients are still on the operating table
- Initial pilot launches across 5 specialist medical centres in England
The National Health Service (NHS) in England has begun rolling out a rapid diagnostic test for brain tumours that slashes the time needed for accurate results from up to eight weeks down to just two hours. This new technology spares patients weeks of agonizing uncertainty and allows them to commence vital treatments such as radiotherapy and chemotherapy much sooner.
Steve Palmer, a 55-year-old from Nottingham, is among the first to benefit from this innovation, which allowed surgeons to obtain his test results while he was still undergoing surgery to remove the tumour.
"Getting that quick diagnosis removed weeks of anxiety."
Steve Palmer
Stock photo for illustration only, not from the actual event
According to NHS England, the genomic test works by rapidly analyzing the genetic code of a tumour sample and will be piloted across specialist medical centres in England. There are approximately 150 different types of brain tumours ranging from slow-growing to aggressive cancers, each demanding a distinct treatment approach.
Steve was diagnosed with a grade 4 glioblastoma after collapsing at the gym. Neurosurgeon Dr. Stuart Smith explained that identifying the specific tumour type while the patient remains on the operating table directly influences surgical strategy. For curable tumour types, surgeons must operate as radically as possible, whereas more aggressive and inoperable cases require a cautious approach to minimize brain damage.
Modern genomic sequencing technologies—such as the shoebox-sized Oxford Nanopore sequencer combined with software developed by the University of Nottingham—represent a fundamental paradigm shift from traditional microscopic pathology. By passing DNA molecules through tiny nanopores to reveal unique genomic fingerprints, clinicians gain actionable molecular insights in minutes rather than weeks, paving the way for precise personalized oncology.
Source: BBC Health
Found something wrong in this article? Report an issue with this article
Comments
Leave a Comment